The FDA has fast-tracked approval of Novo Nordisk's drug Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), affecting 5% of US adults. This is the first GLP-1 class therapy approved for MASH aimed at improving liver function. Preliminary studies have shown promising results, and Novo Nordisk has already applied for approval in Europe and Japan, expecting final trial results in 2029.
Sources
Latest News
10:16
Carlos Alcaraz and Daniil Medvedev made winning starts at the ATP Finals
10:06
EBRD: Emerging economies risk missing out on the AI and defense boom due to insufficient infrastructure and financing
10:02
Health authorities are launching inspections in 25 counties after patients reported fictitious medical services on the CNAS platform
10:00
Theo Rose, criticized after the concert at Sala Palatului in Bucharest because of an artistic moment in which children went on stage in pioneer uniforms
09:27
United Airlines reported a widespread systems outage that caused delays to the departure of some flights.
See more news